neuropathy semaglutide 🔔 Medicine Safety Alert Risk of nonarteritic anterior ischemic

DOI: 10.1016/j.phrs.2025.107927,

Abstract Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk

Subsequent to its initial characterization, research demonstrated that purified GIP stimulated glucose-dependent insulin secretion defining the protein as an incretin, characteristic of GLP-1

Alternative approaches such as overlap weights could restrict analyses to patients with genuine clinical equipoise (4, 5)

They also decrease clumping of platelets which can contribute to a lower risk of stroke

Talk to your doctor first if youre pregnant, nursing, or managing a medical condition